Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JMI
|
|||
| Former ID |
DCL000988
|
|||
| Drug Name |
SLV-310
|
|||
| Synonyms |
L001635; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Discontinued in Phase 2 | [1] | |
| Company |
Solvay Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H24FN3O2
|
|||
| Canonical SMILES |
C1CN(CC=C1C2=CNC3=C2C=C(C=C3)F)CCCCN4C(=O)C5=CC=CC=C5C4=O
|
|||
| InChI |
1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
|
|||
| InChIKey |
NECJNLXOJRDELU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 264869-71-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.